Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.

Naqi N, Ahmad S, Shah I, Khattak J.

J Coll Physicians Surg Pak. 2013 Jun;23(6):397-400. doi: 06.2013/JCPSP.397400.

PMID:
23763798
2.

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M.

Haematologica. 2007 Jan;92(1):35-41.

3.
4.

Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.

Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M.

Ann Hematol. 2011 Jun;90(6):685-91. doi: 10.1007/s00277-010-1113-z.

PMID:
21072518
5.

Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.

Müller-Beissenhirtz H, Kasper C, Nückel H, Dührsen U.

Ann Hematol. 2005 Nov;84(12):796-801.

PMID:
16041531
6.

Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.

Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM.

J Clin Oncol. 2009 Mar 20;27(9):1456-61. doi: 10.1200/JCO.2008.20.3778.

7.

Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.

Di Renzo N, Brugiatelli M, Montanini A, Vigliotti ML, Cervetti G, Liberati AM, Luminari S, Spedini P, Giglio G, Federico M.

Leuk Lymphoma. 2006 Mar;47(3):473-9.

PMID:
16396771
8.

High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.

Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, Matteucci P, Grisanti S, Valagussa P, Bonadonna G, Gianni AM.

Eur J Haematol Suppl. 2001 Jul;64:51-5.

PMID:
11486403
9.
10.

Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.

Kim KH, Joo YD, Sohn CH, Shin HJ, Chung JS, Cho GJ, Shin SH, Kim YS, Lee WS.

Korean J Intern Med. 2009 Mar;24(1):37-42. doi: 10.3904/kjim.2009.24.1.37.

11.
12.

Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Hainsworth JD, Burris HA 3rd, Erland JB, Baker M, Scullin DC Jr, Shaffer DW, Greco FA; Minnie Pearl Cancer Research Network..

Cancer Invest. 2003 Apr;21(2):193-9.

PMID:
12743984
13.

Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group.

Papageorgiou ES, Tsirigotis P, Dimopoulos M, Pavlidis N, Fountzilas G, Papageorgiou S, Economopoulos T; Hellenic Cooperative Oncology Group..

Eur J Haematol. 2005 Aug;75(2):124-9.

PMID:
16000128
14.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
15.

Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children.

Jaffray M, Buchbinder N, Lutun A, Schneider P, Piquenot JM, Vannier JP.

Ann Hematol. 2015 Aug;94(8):1401-6. doi: 10.1007/s00277-015-2362-7.

PMID:
25862234
16.

A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.

Validire P, Fermé C, Brice P, Diviné M, Gabarre J, Bouabdallah K, Fitoussi O, Chaoui D, Pacquement H, Soussain C, Carde P, Salhi R, Zanni M, Decaudin D.

Anticancer Drugs. 2008 Mar;19(3):309-15.

PMID:
18510178
17.

Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.

Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, Todisco E, Bramanti S, Mazza R, Russo F, Timofeeva I, Santoro A.

Am J Hematol. 2007 Feb;82(2):122-7.

18.

High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.

Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.

Eur J Haematol Suppl. 2001 Jul;64:28-32.

PMID:
11486397
19.

A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.

Pasricha SR, Grigg A, Catalano J, Leahy M, Underhill C, Arthur C, D'Rozario J, Lowenthal R, Reed K, Spencer A.

Cancer. 2008 Dec 1;113(11):3192-8. doi: 10.1002/cncr.23915.

20.

Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.

Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group..

J Clin Oncol. 2004 Jun 15;22(12):2348-56.

PMID:
15197195
Items per page

Supplemental Content

Support Center